## L-Carnitine-d<sub>3</sub> hydrochloride

Cat. No.:	HY-B1453S	
CAS No.:	350818-62-1	
Molecular Formula:	C <sub>7</sub> H <sub>13</sub> D <sub>3</sub> CINO <sub>3</sub>	∖∕ QH Q
Molecular Weight:	200.68	
Target:	Reactive Oxygen Species; Isotope-Labeled Compounds	
Pathway:	Immunology/Inflammation; Metabolic Enzyme/Protease; NF-кB; Others	D
Storage:	4°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

In Vitro H <sub>2</sub> O: 250 m Preparing Stock Solu	H <sub>2</sub> O : 250 mg/mL (1245.76 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
		1 mM	4.9831 mL	24.9153 mL	49.8306 mL
		5 mM	0.9966 mL	4.9831 mL	9.9661 mL
		10 mM	0.4983 mL	2.4915 mL	4.9831 mL
	Please refer to the sol	ubility information to select the app	propriate solvent.		
In Vivo	1. Add each solvent o Solubility: 100 mg,	one by one: PBS /mL (498.31 mM); Clear solution; Ne	ed ultrasonic		

Description	L-Carnitine-d <sub>3</sub> (hydrochloride) is the deuterium labeled L-Carnitine hydrochloride[1].			
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.



## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA